|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.3400 - 0.4200|
|52 Week Range||0.3400 - 0.5100|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
JR Rahn, Co-Founder and Co-CEO of MindMed, joins Yahoo Finance's The Final Round to discuss the market for psychedelic-based pharmaceuticals, navigating government regulation, and the U.S. opioid crisis.
Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the signing of a multi-year, branch exclusive collaboration with the laboratory of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland.
Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its audited consolidated financial statements (the "Financial Statements") and accompanying management's discussion and analysis (the "MD&A;") for the period from May 30, 2019, date of incorporation, to December 31, 2019 (the "period ended December 31, 2019"). All financial figures contained herein are expressed in U.S. dollars ("USD") unless otherwise noted.
Mind Medicine (MindMed), Inc. (NEO: MMED; OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced that the company has begun enrollment in further human safety studies of 18-MC, the company's orally-active drug candidate for the treatment of opioid use disorders.
Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations
Shark Tank's Kevin O'Leary and Bruce Linton are betting big on psychedelics.